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Bisphosphonates target and bind avidly to the mineral (hydroxyapatite) found in bone. This 
targeting ability has been exploited to design and prepare bisphosphonate conjugate prodrugs 
to deliver a wide variety of drug molecules selectively to bones. It is important that conjugates 
be stable in the blood stream and that conjugate that is not taken up by bone is eliminated 
rapidly. The prodrugs should release active drug at a rate appropriate so as to provide efficacy. 
Radiolabelling is the best method to quantify and evaluate pharmacokinetics, tissue 
distribution, bone uptake and release of the active drug(s). Recent reports have described 
bisphosphonate conjugates derived from the antiresorptive drug, alendronic acid and anabolic 
prostanoid drugs that effectively deliver prostaglandins and prostaglandin EP4 receptor 
agonists to bone and show enhanced anabolic efficacy and tolerability compared to the drugs 
alone. These conjugate drugs can be dosed infrequently (weekly or bimonthly) whereas the free 













drug = active drug molecule
Introduction: 
Treating diseases of the bone can be difficult due to relatively low vascularization and the 
physical barriers of penetrating the tissue. High doses of systemic drugs may be necessary to 
provide efficacy in bone and in the case of drugs with important systemic effects or side effects 
these may limit or exclude their use in treating conditions of the bones. Many researchers in 
the past have attempted to identify chemical structural elements that may preferentially bind 
to the hydroxyapatite mineral in bone as a way to target drugs to bone [1, 2]. Some 
polyhydroxy containing molecules such as tetracyclines [3] or poly-acidic peptides [4, 5], 
polymers [6, 7], hydroxylated heterocycles [8] and monophosphonates [9] have been found to 
bind to apatite and have been studied but binding to hydroxyapatite may in fact impair or block 
biological activity of such compounds. One structure type that has found considerable success 
as a bone targeting moiety is the class of drugs known as bisphosphonates. Bisphosphonates 
and hydroxy-bisphosphonates represent a non-hydrolyzable analog of pyrophosphate and bind 
avidly to hydroxyapatite. Once complexed to hydroxyapatite the bisphosphonates are 
essentially irreversibly bound and can only be liberated in the course of bone turnover by 
osteoclasts, cells that dissolve the mineral in bone with hydrochloric acid as part of the bone 
resorption process [10]. Aminoalkyl 1-hydroxy-1,1-bisphosphonates such as alendronic acid 
(FosamaxTM) are effective antiresorptive drugs and have been in wide use for decades [11]. 
Bisphosphonates have been used as a vehicle to selectively deliver proteins [12], liposomes 
[13], nanoparticles [14] and small molecules to bone by virtue of their bone binding properties 
and can serve as a point of attachment for a wide variety of drugs and active molecules 
including proteasome inhibitors [15], anticancer drugs [16, 17], analgesics [18] and antibiotics 
[19–21].  
Bisphosphonates such as alendronate are very polar molecules and are poorly absorbed 
following oral dosing and are rapidly eliminated from the body if they do not bind first to bone 
[22–24]. Radiolabelling studies have shown that 40 - 50% of alendronate is taken up by bones 
after systemic dosing [23]. Conjugates with bisphosphonates are expected to also not be well 
absorbed and are usually studied after IV dosing.  
An ideal drug-bisphosphonate prodrug for bone-targeted delivery would have the following 
properties: 
1) Be tethered by a linker element that is stable in the blood stream such that within a 
short time (< 1 day) the molecule will either bind to bone intact or be largely eliminated 
intact from the body, 
2) Be inactive in so far as the activity of the drug to be delivered is concerned, 
3) Once bound to bones, release the active drug in a slow and sustained manner. An ideal 
half time for release of about 4-7 days would support infrequent dosing of once a week 
or twice a month,  
4) Be sufficiently potent so that the overall dose of conjugate (and body load of 
bisphosphonate in bones) would be relatively low and within the scale of doses of 
bisphosphonates that have been shown to be safe in the past, 
5) The drug to be delivered is on its own poorly distributed to bone, or if dosed as a free 
drug in the systemic circulation, exhibits unacceptable side effects that limit its use. 
To quantitatively assess stability and integrity of a drug-bisphosphonate conjugate prodrug it is 
preferable to radiolabel the drug (and also, ideally, the bisphosphonate or linker component). 
The radiolabel(s) can then be used to quantitatively assess tissue distribution, bone uptake and 
elimination after dosing, and to demonstrate release of the bone-bound drug to determine the 
half-time for drug release.  While many researchers have designed and synthesized 
bisphosphonate-drug conjugates and some have evaluated their effects in vivo (vide supra), 
very few have evaluated biodistribution and elimination of the prodrug in vivo or quantified 
bone exposure or drug release in the bones.  
One class of drugs that have been successfully targeted to bones both via bisphosphonates (and 
also via conjugation to polyanionic polymers [6]) are the bone anabolic prostaglandins related 
to prostaglandin E2 (PGE2). PGE2 was shown to be anabolic for bone in animals [25, 26] and in 
humans [27]. However, PGE2 interacts with 4 distinct receptors in the body and exhibits many 
other physiological effects including muscle contraction and relaxation, hypotension and 
various gastro-intestinal effects that render its use for bone impractical [28].  
 
Bone targeting prodrugs of prostaglandins E2 and E1.  
Some reports have described targeting PGE1 to bone using an fluorescene isothiocyanate(FITC)-
labeled hydroxymethylpolyacrylamide copolymer(P)–Asp8 conjugate (P-Asp8-FITC) [6] where 
the PGE1 was coupled as an ester to the polymer and the fluorescein was used to gain a 
measure of bone attachment. Polyaspartate is known to bind to bone mineral due to its 
polycarboxylate structure. The polypeptide was a potential substrate for cathepsin K (the major 
protease secreted by bone resorbing osteoclast cells) and cleavage of the polymer could 
facilitate liberation of PGE1 especially in areas of high bone turnover. Those authors found that 
a single injection of P-Asp8-FITC-PGE1 in rats resulted in enhanced bone formation (relative to 
vehicle or P-Asp8-FITC) measured 4 weeks later but absolute amounts of polymer that reached 
the bone and of PGE1 that was delivered were not defined [6].  
 
Figure 1: Bone targeting bisphosphonate conjugates derived from PGE2 [29] 
 
In another study, several bone-targeting prodrugs of PGE2 were prepared with the intent of 
devising a dual action prodrug that would release both PGE2 as an anabolic agent and an 
antiresorptive bisphosphonate [29] (Figure 1). One conjugate (1) was prepared where 
alendronic acid was coupled to PGE2 through an amide bond and this conjugate was 
radiolabelled with 3H on PGE2 and 14C on alendronate to allow tracking in vivo. 1 was dosed to 
rats and found to be well taken up by bones (about 12 - 15% of administered dose), but 
tracking of the radiolabels over 4 weeks showed that the tritium (representing PGE2) was not 
released and both labels remained unchanged presumably due to the stability of the amide 
bond in vivo. In the same study a second conjugate (2) was prepared where PGE2 was 
conjugated with a bisphosphonate via an ester bond at the 15-hydroxy group on PGE2. 
Compound 2 was found to be quite stable in blood and a radiolabelled version (synthesized 
from tritiated PGE2) was shown to be taken up into bones (about 3 - 3.5 % of administered 
dose) and then to release the 3H label with a half-time of about 7 days. Whereas PGE2 was 
dosed intraperintonealy at 6 mg/kg (its maximum tolerated dose), the conjugate 2 could be 
dosed intravenously up to 100 mg/kg without overt side effects. Dosing 2 intravenously at 10 
and 100 mg/kg once weekly for 28 days resulted in a dramatic anabolic effect and was shown to 
be more effective as a bone growth stimulant than PGE2 dosed daily at its maximum tolerated 
dose. A mixture of PGE2 and 3 (5 mg/kg each) was dosed once weekly to show the benefit of 
conjugation and showed no significant anabolic or antiresorptive effects at those doses. 
Unfortunately, while prodrug 2 was a potent and well tolerated anabolic agent it did not 
demonstrate antiresorptive activity and was difficult to prepare on larger scale due to the 
sensitivity of PGE2 (a tendency for elimination of the 9-hydroxyl group under acidic or basic 
conditions and facile isomerization of the 5,6 double bond).  
Subsequent to these studies, Machwate et al. [30] demonstrated that PGE2 exerted its anabolic 
effect in bone through agonism at the EP4 receptor subtype and a number of very potent and 
highly selective EP4 receptor agonists were subsequently identified [28]. One of these 
compounds (4) (Figure 2) was much more stable that PGE2 both chemically and metabolically, 
was found to be orally absorbed [31], and was tested in rats for bone effects. Compound 4 
dosed orally at 0.5 mg/kg for 28 days demonstrated anabolic effects similar to PGE2 dosed at 3 
mg/kg (R. Young and G. Rodan, unpublished results). Unfortunately, EP4 selective agonists were 
found to retain some of the systemic and GI side effects of PGE2 and thus far have not been 
developed further for treatment of osteoporosis. 
 
Bone targeting bisphosphonate conjugates delivering EP4 receptor agonists. The option of 
preparing a bone-targeting bisphosphonate conjugate as a prodrug to deliver an EP4 agonist to 
bones was revisited in a recent series of studies. In particular, the enhanced stability of the 
selective agonists 4 and its analog 5 [32] allowed synthesis of prodrug conjugates designed to 
liberate both the EP4 agonist and an active  
 
Figure 2: Bone targeting bisphosphonate conjugate prodrugs based on selective EP4 agonist 5. 
 
bisphosphonate, alendronate. Two conjugates were reported [33] (Figure 2). One conjugate 
(C1) employed a bifunctional linker group (LNK), 4-hydroxyphenylacetic acid, where the 
carboxyl function of LNK was esterified to the 15-hydroxyl group of 5 and the phenolic group on 
LNK was attached to alendronic acid via a carbamate group.  A second conjugate (C2) was 
prepared where 5 (as ethyl ester) and alendronate were directly coupled via a carbamate 
functionality. It was anticipated that the carbamate functions could be hydrolyzed in vivo based 
on the known in vivo conversion of carbamate prodrugs such as bambuterol [34]. In the case of 
C1, ester hydrolysis (as demonstrated for PGE2 conjugate 2) would liberate 5 while carbamate 
hydrolysis would liberate alendronate. In the case of C2, hydrolysis of the carbamate would 
liberate both parts simultaneously (Figure 2). Synthesis of conjugate C1 was straightforward 
aided by the stability of 5. The pharmacokinetics and biodistribution of C1 and C2 in rats was 
also reported [35]. C1 was prepared in tritium labeled (on the EP4 agonist moiety) and in dual 
(3H/14C) labelled forms with tritium label in the EP4 agonist (5) part of the molecule and 14C 
incorporated into the carbamate function. It was expected that the rate of hydrolysis of the 
ester bond joining 5 to the linker could be considerably faster than hydrolysis of the carbamate 
moieties in C1 or C2. Radiolabelled C2 was prepared from tritium-labelled 5 (as ethyl ester) to 
provide a compound that was tracked in mono-labelled form in vivo. Thus, it was possible to 
demonstrate good stability of C1 and C2 in blood plasma (only 5-10% hydrolysis after 24 hours 
incubation) and to show that the prodrugs bound rapidly and irreversibly to bone powder after 
a few minutes contact. Labelled C1 and C2 were both dosed intravenously to rats and the 
biodistribution and elimination of the labels were tracked in feces, bones and blood. Uptake of 
intact into bones C2 was quite good (9.4% of administered dose) whereas uptake of C1 was 
somewhat less (5.9%). For both C1 analysis of bones after 6 hours showed both 3H and 14C 
labels in a ratio similar to that in the dosed drugs indicating the conjugates had survived intact 
before binding. The radioactivity corresponding to the portion of both C1 and C2 that did not 
bind to bones was rapidly cleared from the systemic circulation with an elimination half-time of 
< 0.5 h and in each case, elimination was presumably via the liver (most of the label was found 
in feces). For C1, the 3H/14C ratios found in blood and bones was similar to that originally dosed. 
In the case of the experiment with C2 [33], the tritium label in bone diminished slowly with an 
estimated half-time of 28 days. This was quite slow but indicated that the prodrug might be 
amenable to a once a month dosing regimen.  In the case of C1, the tritium label was reduced in 
the bones at a much faster rate than the 14C found in the linker [35]. The half-times for loss of 
label were 5 days and 22 days respectively. It is interesting to note that the loss of label from 
the bones for both drugs appeared to be biphasic and more rapid during the first two weeks 
and then slowing considerably. This may possibly be due to new bone overgrowing the bound 
prodrug and eventually isolating the bound conjugate from access to hydrolytic enzymes.  
In a recent study, another EP4 agonist-alendronate prodrug conjugate (6) was reported [36] 
where the two drugs were linked via a peptide linker (Figure 3). The peptide linker was based 
on Cbz-Leu-Phe-(7-amino-4-methylcoumarin), a known dipeptide substrate of cathepsin K, the 
proteolytic enzyme secreted by bone-resorbing osteoclasts. The carboxybenzyloxycarbonyl 
(Cbz) N-capping group was substituted with an acetic acid group on the Cbz and was attached 
to 6 via an ester bond as was done in C1. The peptide was designed such that cathepsin K would 
cleave the C-terminal amide to liberate a 4-aminobenzyloxycarbamyl alendronate moiety which 
would then self-immolate to liberate active alendronate (Figure 3). This novel conjugate was 
synthesized in dual radiolabelled form with tritium on the EP4 agonist and 14C in the carbamyl 
group attached to alendronate. In this manner one could monitor both hydrolytic events by loss 
of label in the bones after binding. Unfortunately, the conjugate was found to be only 
moderately stable in rat plasma with 44% liberation of tritium (i.e. 5) in 4 hrs.  
 
Figure 3: Bone targeting prodrug conjugate liberating alendronate by action of cathepsin K [36] 
 
and 53 % over 24 hrs. Nonetheless the dual labelled conjugate was dosed to rats and notably, 
the ratio of labels found in the blood and liver were essentially the same as dosed, suggesting 
the conjugate was largely intact until eliminated. In contrast, the ratio of labels in the bones 
after 6 h indicated about 50% of 5 was lost prior to binding of the conjugate to bone and while 
5% of the 14C label was found in bones 6 h post dose, only about 2.5% of the 3H label was 
found. The decay (release) of labels was monitored and the loss of 3H proceeded with a 4.4 day 
T½ (much as was seen with C1). However, the release of the 14C label was also quite fast (T½ 5 
days) indicating that the proteolytic cleavage of the peptide was quite efficient. While, in the 
end, the conjugate was not deemed suitable for a follow up efficacy trial, due to the significant 
loss of the EP4 agonist before bone binding, it did demonstrate the feasibility of using cathepsin 
K as an enzymatic trigger to release a bone-bound drug from a conjugate bound to bone. This 
could lead others to use the technique in the future. 
 In vivo Anabolic Efficacy studies with EP4 agonist-bisphosphonate conjugate prodrugs 
The stability and pharmacokinetic results obtained with conjugates C1 and C2 indicated that 
they were viable candidates for follow up efficacy studies in the ovariectomized rat model of 
osteoporosis.  In an initial curative 6-week study [37] female rats were ovariectimized (had their 
ovaries surgically removed) and were kept 7 weeks post operation to allow for osteopenia to be 
established. Six groups of 6-8 rats were tested including one group that had undergone a sham 
operation (sham group) and an ovariectomized (OVX) group that were dosed IV with vehicle 
(vehicle control). In other groups, C1 was dosed at 5 mg/kg (low dose) and 25 mg/kg (high dose) 
once weekly. However, in the high dose group the first two doses at 25 mg/kg was not well 
tolerated (local irritation and hind limb swelling) and this dose was subsequently reduced to 15 
mg/kg biweekly until the end of the study. Another group was dosed iv, once weekly, with a 
mixture of 2.5 mg/kg of 5 (as ethyl ester, hereafter referred to as EP4a) and 2.5 mg/kg the 
linker unit bound to alendronic acid (LNK-ALN) to test the effect of conjugation. The sixth group 
was dosed subcutaneously and daily with 4 mg/kg PGE2 as a positive control. At 12 days and 2 
days before termination, the rats were injected with Calcein green to fluorescently mark the 
bones to assess rates of growth. 
 
 
Figure 4: C1 effects in bone in rat ovariectomized (OVX) rat assay: Representative images from 
microCT from the proximal tibial metaphysis. From left to right: sham rat, OVX rat and OVX rat 
treated with C1 conjugated drug. 
 
The results showed curative anabolic effects (Figure 4). Weekly administration of C1 conjugate 
dose-dependently increased bone volume in trabecular bone, and partially or completely 
reversed OVX-induced bone loss in the tibial metaphysis and in the lumbar vertebrae and 
improved vertebral mechanical strength. The conjugate also dose-dependently stimulated 
endocortical woven bone formation and intracortical remodeling in cortical bone. The low dose 
treatment increased the mechanical strength while the high dose also increased strength but 
compromised bone material properties. Conjugation between the EP4a and ALN-LK 
components was crucial to the drug’s anabolic efficacy. The low dose gave results comparable 
to that of the PGE2 positive control despite the fact that the maximum dose of EP4a was only 
10% of the PGE2 dose on a weekly basis. This study with C1 conjugate represented the first time 
that a combined therapy using an anabolic agent and the anti-resorptive compound ALN has 
shown significant anabolic effects which reversed established osteopenia.  
In a second and longer (12 week) curative OVX rat study [38] C1 was dosed iv at 5 mg/kg once 
weekly (C1 high) and twice monthly (C1 low) and C2 was dosed at 15 mg/kg twice monthly (C2 
high) and once monthly (C2 low). These groups were compared to OVX rats dosed with a 
mixture of alendronate and 5 ethyl ester (EP4a) (0.75 mg/kg each dosed every two weeks, a 
dose calculated to mimic the degree of exposure of rats to 5 and ALN in the C2 high dose 
experiment). There were also with sham (operated but non-OVX) and vehicle OVX rat controls. 
In this study results from the C1 weekly dose recapitulated the results obtained in the first 
study but the twice-monthly dose group showed no significant effects on cortical and 
trabecular bone. The C2 gave minimal effects at either dose as did the unconjugated mixture. It 
thus appeared that the amount of 5 and ALN released from C2 was too small to exert a 
measurable effect and that the C1 dose of 5 mg/kg was optimal. Because 5 was released at the 
same time as the alendronate, it also appears that they functionally antagonized each other 
and therefore showed no significant effects, either anabolic or antiresorptive, on bone. 
    
Conclusions: The studies discussed in this review have shown that a bisphosphonate can 
provide a viable vector for targeting drugs to bones and that it is very important to characterize 
the stability of such conjugates in the blood stream and to also to monitor the amount of 
conjugate that reaches and binds to the bone as well as the rate at which the prodrug releases 
its components. The percentage of dose that binds to bones can vary quite considerably (as 
seen from 2.5 to about 10%) and generally is less than observed for alendronate itself. Also, 
these conjugates tend to be rapidly eliminated in feces whereas alendronate is largely 
eliminated in the urine. These differences may correlate with polarity and possibly with plasma 
protein binding as the conjugates are generally much more lipophilic than the bisphosphonate 
alone. In the best conditions such as was found with C1, the bone targeted prodrug approach 
can deliver drugs to bone and provide sustained local release, efficacy and avoid unwanted 
systemic side effects. [38]. 
Future prospects: The next step for the use of bisphosphonates to target therapeutics to bone 
is to advance drugs such as C1 into human clinical trials to definitively provide human proof of 
principle and to demonstrate efficacy and tolerability in treating human diseases of the bone. A 
logical indication for C1 would be osteoporosis but the hurdles to bring a new drug for 
osteoporosis to the market are immense. Very large and long duration clinical trials are needed 
to support developing a new osteoporosis drug with such a high level of expense and risk that 
only the largest pharmaceutical companies can contemplate such a project. An alternative and 
exciting indication may be advancing C1 for treatment for the osteogenesis imperfecta (OI), 
otherwise known as brittle bone disease, an orphan congenital disease which afflicts thousands 
of children and where treatment options are few. Alendronate is used as an antiresorptive to 
treat OI in children [39] and several bone anabolic biologic drugs such as teriparatide [40] and 
the sclerostin antibody BPS804 [41] have shown promise in clinical trials to build density bone 
in adult OI patients. A targeted combination drug such as C1 may have a useful role to play in 
treatment of OI.  
As linker technologies improve, bisphosphonates will be used to target other drugs to bone 
including anticancer drugs and antibiotics. The key to success will be to build prodrugs that are 
very stable in the bloodstream, are well taken up by bone and any drug not taken up should be 
rapidly eliminated intact in an inactive form. The bone-bound prodrug will then give sustained 
release of active agent and should thus achieve at least a ten-fold dose (exposure) advantage 
compared to dosing free drug alone. We are now developing new, very stable linker 
technologies that spontaneously (but slowly) release a wide variety of drug molecules and do 
not require enzymatic cleavage.  These linkers will be “tunable” to provide a wide range of half-
ties of release and further revolutionize the field. 
 
Highlights:  
 PGE2 receptor EP4 agonists are anabolic in bones but retain some side effects 
 EP4 agonists conjugated with bisphosphonates target bones selectively 
 EP4 agonist-alendronate conjugates are effective bone anabolics when dosed 
weekly 
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